Karen Krasney Sells Shares of Capricor Therapeutics
Karen Krasney sold 24,100 shares of Capricor Therapeutics on June 25, 2026.
Key Points
- Karen Krasney, EVP and General Counsel, sold 24,100 shares of Capricor Therapeutics, Inc. on June 25, 2026.
- Capricor Therapeutics, Inc. has a market cap of approximately $1.53 billion and a 52-week high of $40.37.
- Analysts from B. Riley Securities, Piper Sandler, and HC Wainwright & Co. maintain a 'buy' rating on Capricor Therapeutics.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Karen Krasney, the Executive Vice President and General Counsel at Capricor Therapeutics, Inc. (NasdaqGS: CAPR), sold 24,100 shares of the company on June 25, 2026. The transaction was not part of a pre-planned trading program. Shares of Capricor traded near $26.44 on Tuesday.
Capricor Therapeutics, Inc. Stock Up 175.7%
Shares of Capricor Therapeutics, Inc. traded near $26.44 on Tuesday. The biotechnology company, which focuses on developing therapies for Duchenne muscular dystrophy and other serious conditions, has a market cap of approximately $1.53 billion. Although the company isn't currently profitable, it has a forward P/E ratio of -41.17. The stock has experienced significant volatility, with a 52-week low of $4.30 and a high of $40.37. Its 50-day moving average is $30.15, while the 200-day moving average stands at $21.95.
$CAPR stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at Capricor Therapeutics, Inc.
On June 25, 2026, both Karen Krasney, EVP and General Counsel, and Anthony Bergmann, CFO, were involved in transactions at Capricor Therapeutics. Krasney sold 24,100 shares at an average price of $30.38, while Bergmann also sold the same number of shares at the same price. Both insiders had previously acquired 24,100 shares at $3.18 each on the same day.
Analysts Set New Price Targets
Analysts have maintained a positive outlook on Capricor Therapeutics, Inc. On March 13, 2026, B. Riley Securities maintained a 'buy' rating with a price target of $63.00. Piper Sandler reiterated its 'buy' rating with a target of $58.00 on the same day. Earlier in March, HC Wainwright & Co. also reiterated a 'buy' rating, setting a target price of $60.00. The consensus recommendation remains a 'strong buy', with a mean target price of $53.60 based on 10 analyst opinions.
About Capricor Therapeutics
Capricor Therapeutics, Inc. is a clinical-stage biotechnology firm based in San Diego, California. It focuses on developing innovative cell and exosome-based therapies for serious diseases like Duchenne muscular dystrophy. Its lead product candidate, Deramiocel, is in phase 3 clinical trials. The company also explores exosome-based treatments and vaccines, including a preclinical SARS-CoV-2 vaccine candidate. Dr. Linda Marbán leads the company as CEO, overseeing a team of 231 employees.
Bottom Line
Karen Krasney's recent share sale at Capricor Therapeutics highlights insider activity at the company. Despite the insider transactions, analysts remain bullish on the stock, maintaining 'buy' ratings with high price targets. Investors often track such transactions for insights, but remember that 13F and insider filings reflect past actions, not necessarily current positions.
Get Capricor Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CAPR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.